Osteoporosis in men: Suspect secondary disease first
Angelo Licata, MD, PhD
Department of Endocrinology, Diabetes, and Metabolism, The Cleveland Clinic
Address: Angelo Licata, MD, PhD, Department of Endocrinology, Diabetes, and Metabolism, A30, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195
The author has indicated that he has received grant or research support from Merck, Lilly, Pfizer, Aventis, Wyeth Ayerst, and Novartis corporations.
This paper discusses treatment that is not approved by the US Food and Drug Administration for the use under discussion.
ABSTRACTSince osteoporosis in men is more often secondary rather than primary (idiopathic), we need to seek the underlying cause through the history and laboratory testing. Treatment options are similar to those for women, although data are limited about their efficacy in men.